The ABPI responded to Radio 4's File on Four programme on opioids, which examined whether there are any similarities between the way in which opioid medications are being marketed by pharmaceutical companies in the US and the UK.
The Migration Advisory Committee has published their full review of the shortage occupation list (SOL) and recommended that a number of fields be added to the list.
Today (23 May), the ABPI and the AHSN Network publish a new guide to cross-sector working between NHS Sustainable Transformation Partnerships (STPs), Integrated Care Systems (ICSs) and industry. The guide sets out governance and process recommendations to make collaboration more straightforward.
Life sciences is among a select group of highly innovative industries linked to science and tech which could be responsible for a new wave of growth worth an extra £14 billion a year to the UK economy by 2025.
Health Secretary Matt Hancock has announced that all opioid medicines in the UK will carry prominent warnings on the labels saying they can cause addiction.
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
King’s College London, Wellcome and pharmaceutical company MSD announced a collaboration and licencing deal today that could lead to a new class of pain medications.
“Pharmaceutical companies have done everything in their power to prepare for a ‘no deal’ Brexit. This includes increasing stocks of medicines, changing and adding new supply routes and duplicating manufacturing processes here and in Europe." MORE >
The Topol review of digital training needs for the NHS is published today. It says that cross-sector collaboration is vital - Andrew Croydon, Director of Skills and Education policy at the ABPI, agrees.
A Europe-wide initiative to protect patients and public health from falsified or fake medicines goes live on Saturday 9 February 2019, making the medicines supply chain across Europe safer than ever before.